Outcomes and Characteristics of Non-Melanoma Skin Cancers in Patients with Myeloproliferative Neoplasms on Ruxolitinib.
Rampotas A., Carter-Brzezinski L., Somervaille TC., Forryan J., Panitsas FP., Harrison CN., Witherall R., Innes AJ., Wallis L., Butt NM., Psaila B., Mead AJ., Carter M., Godfrey AL., Laing H., Garg M., Francis S., Ewing J., Teh CH., Cowan HB., Dyer P., McConville C., Wadelin F., Ali S., McGregor A., Kulakov E., McLornan DP., Lambert J.
Non-melanoma skin cancers in ruxolitinib-treated MPN patients behave aggressively, with adverse features and high recurrence. In our cohort, mortality from metastatic NMSC exceeded that from myelofibrosis . Vigilant skin assessment, counselling on NMSC risks, and prospective ruxolitinib-NMSC studies are crucial.